X

Trial Profile

Open-Label trial to Determine the Long-term Safety of Safinamide in Parkinson's Disease Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Safinamide (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Merck Serono; Newron Pharmaceuticals; Newron Sweden AB

Most Recent Events

19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
11 Aug 2012 Company (Newron Pharmaceuticals) added as reported by European Clinical Trials Database record.
30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com